S&P 500   3,768.47 (-1.34%)
DOW   30,924.14 (-1.11%)
QQQ   304.10 (-1.64%)
AAPL   120.13 (-1.58%)
MSFT   226.73 (-0.36%)
FB   257.64 (+0.87%)
GOOGL   2,033.93 (+1.12%)
TSLA   621.44 (-4.86%)
AMZN   2,977.57 (-0.91%)
NVDA   494.81 (-3.39%)
BABA   230.50 (-2.44%)
CGC   31.01 (-6.71%)
GE   13.57 (+0.97%)
MU   84.33 (-5.36%)
NIO   39.28 (-5.42%)
AMD   77.75 (-3.85%)
T   28.92 (+0.70%)
F   11.93 (-1.97%)
ACB   9.82 (-6.12%)
DIS   188.03 (-2.20%)
BA   224.71 (-1.68%)
NFLX   511.29 (-1.81%)
BAC   36.50 (+0.22%)
S&P 500   3,768.47 (-1.34%)
DOW   30,924.14 (-1.11%)
QQQ   304.10 (-1.64%)
AAPL   120.13 (-1.58%)
MSFT   226.73 (-0.36%)
FB   257.64 (+0.87%)
GOOGL   2,033.93 (+1.12%)
TSLA   621.44 (-4.86%)
AMZN   2,977.57 (-0.91%)
NVDA   494.81 (-3.39%)
BABA   230.50 (-2.44%)
CGC   31.01 (-6.71%)
GE   13.57 (+0.97%)
MU   84.33 (-5.36%)
NIO   39.28 (-5.42%)
AMD   77.75 (-3.85%)
T   28.92 (+0.70%)
F   11.93 (-1.97%)
ACB   9.82 (-6.12%)
DIS   188.03 (-2.20%)
BA   224.71 (-1.68%)
NFLX   511.29 (-1.81%)
BAC   36.50 (+0.22%)
S&P 500   3,768.47 (-1.34%)
DOW   30,924.14 (-1.11%)
QQQ   304.10 (-1.64%)
AAPL   120.13 (-1.58%)
MSFT   226.73 (-0.36%)
FB   257.64 (+0.87%)
GOOGL   2,033.93 (+1.12%)
TSLA   621.44 (-4.86%)
AMZN   2,977.57 (-0.91%)
NVDA   494.81 (-3.39%)
BABA   230.50 (-2.44%)
CGC   31.01 (-6.71%)
GE   13.57 (+0.97%)
MU   84.33 (-5.36%)
NIO   39.28 (-5.42%)
AMD   77.75 (-3.85%)
T   28.92 (+0.70%)
F   11.93 (-1.97%)
ACB   9.82 (-6.12%)
DIS   188.03 (-2.20%)
BA   224.71 (-1.68%)
NFLX   511.29 (-1.81%)
BAC   36.50 (+0.22%)
S&P 500   3,768.47 (-1.34%)
DOW   30,924.14 (-1.11%)
QQQ   304.10 (-1.64%)
AAPL   120.13 (-1.58%)
MSFT   226.73 (-0.36%)
FB   257.64 (+0.87%)
GOOGL   2,033.93 (+1.12%)
TSLA   621.44 (-4.86%)
AMZN   2,977.57 (-0.91%)
NVDA   494.81 (-3.39%)
BABA   230.50 (-2.44%)
CGC   31.01 (-6.71%)
GE   13.57 (+0.97%)
MU   84.33 (-5.36%)
NIO   39.28 (-5.42%)
AMD   77.75 (-3.85%)
T   28.92 (+0.70%)
F   11.93 (-1.97%)
ACB   9.82 (-6.12%)
DIS   188.03 (-2.20%)
BA   224.71 (-1.68%)
NFLX   511.29 (-1.81%)
BAC   36.50 (+0.22%)
Log in
NASDAQ:MTEX

Mannatech Competitors

$18.34
-0.18 (-0.97 %)
(As of 03/4/2021 04:30 PM ET)
Add
Compare
Today's Range
$18.10
Now: $18.34
$18.46
50-Day Range
$17.75
MA: $18.39
$19.21
52-Week Range
$6.49
Now: $18.34
$20.32
Volume1,428 shs
Average Volume2,403 shs
Market Capitalization$38.29 million
P/E Ratio5.64
Dividend Yield3.46%
Beta1.09

Competitors

Mannatech (NASDAQ:MTEX) Vs. CGC, APHA, TLRY, CRON, USNA, and ACB

Should you be buying MTEX stock or one of its competitors? Companies in the industry of "medicinals & botanicals" are considered alternatives and competitors to Mannatech, including Canopy Growth (CGC), Aphria (APHA), Tilray (TLRY), Cronos Group (CRON), USANA Health Sciences (USNA), and Aurora Cannabis (ACB).

Mannatech (NASDAQ:MTEX) and Canopy Growth (NASDAQ:CGC) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, risk, dividends, earnings and valuation.

Valuation and Earnings

This table compares Mannatech and Canopy Growth's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Mannatech$157.73 million0.24$3.29 millionN/AN/A
Canopy Growth$297.34 million39.20$-993,370,000.00$1.3223.49

Mannatech has higher earnings, but lower revenue than Canopy Growth.

Risk & Volatility

Mannatech has a beta of 1.09, suggesting that its stock price is 9% more volatile than the S&P 500. Comparatively, Canopy Growth has a beta of 2.44, suggesting that its stock price is 144% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and target prices for Mannatech and Canopy Growth, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Mannatech0000N/A
Canopy Growth510412.05

Canopy Growth has a consensus target price of $38.5667, suggesting a potential upside of 24.37%. Given Canopy Growth's higher probable upside, analysts plainly believe Canopy Growth is more favorable than Mannatech.

Profitability

This table compares Mannatech and Canopy Growth's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Mannatech5.04%28.69%11.99%
Canopy Growth-312.84%-13.11%-9.66%

Insider & Institutional Ownership

15.0% of Mannatech shares are owned by institutional investors. Comparatively, 10.2% of Canopy Growth shares are owned by institutional investors. 45.8% of Mannatech shares are owned by insiders. Comparatively, 0.3% of Canopy Growth shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Mannatech beats Canopy Growth on 7 of the 13 factors compared between the two stocks.

Mannatech (NASDAQ:MTEX) and Aphria (NASDAQ:APHA) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, risk, dividends, earnings and valuation.

Valuation and Earnings

This table compares Mannatech and Aphria's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Mannatech$157.73 million0.24$3.29 millionN/AN/A
Aphria$405.96 million13.04$-63,210,000.00($0.06)-278.50

Mannatech has higher earnings, but lower revenue than Aphria.

Risk & Volatility

Mannatech has a beta of 1.09, suggesting that its stock price is 9% more volatile than the S&P 500. Comparatively, Aphria has a beta of 2.67, suggesting that its stock price is 167% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and target prices for Mannatech and Aphria, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Mannatech0000N/A
Aphria03602.67

Aphria has a consensus target price of $17.7857, suggesting a potential upside of 4.01%. Given Aphria's higher probable upside, analysts plainly believe Aphria is more favorable than Mannatech.

Profitability

This table compares Mannatech and Aphria's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Mannatech5.04%28.69%11.99%
Aphria-36.10%-2.30%-1.66%

Insider & Institutional Ownership

15.0% of Mannatech shares are owned by institutional investors. Comparatively, 10.3% of Aphria shares are owned by institutional investors. 45.8% of Mannatech shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Mannatech beats Aphria on 7 of the 12 factors compared between the two stocks.

Mannatech (NASDAQ:MTEX) and Tilray (NASDAQ:TLRY) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, risk, dividends, earnings and valuation.

Valuation and Earnings

This table compares Mannatech and Tilray's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Mannatech$157.73 million0.24$3.29 millionN/AN/A
Tilray$166.98 million23.30$-321,170,000.00($1.69)-13.40

Mannatech has higher earnings, but lower revenue than Tilray.

Risk & Volatility

Mannatech has a beta of 1.09, suggesting that its stock price is 9% more volatile than the S&P 500. Comparatively, Tilray has a beta of 3.12, suggesting that its stock price is 212% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and target prices for Mannatech and Tilray, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Mannatech0000N/A
Tilray210001.83

Tilray has a consensus target price of $18.3078, suggesting a potential downside of 19.63%. Given Tilray's higher probable upside, analysts plainly believe Tilray is more favorable than Mannatech.

Profitability

This table compares Mannatech and Tilray's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Mannatech5.04%28.69%11.99%
Tilray-242.60%-92.70%-20.70%

Insider & Institutional Ownership

15.0% of Mannatech shares are owned by institutional investors. Comparatively, 12.6% of Tilray shares are owned by institutional investors. 45.8% of Mannatech shares are owned by insiders. Comparatively, 16.8% of Tilray shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Mannatech beats Tilray on 7 of the 11 factors compared between the two stocks.

Mannatech (NASDAQ:MTEX) and Cronos Group (NASDAQ:CRON) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, risk, dividends, earnings and valuation.

Valuation and Earnings

This table compares Mannatech and Cronos Group's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Mannatech$157.73 million0.24$3.29 millionN/AN/A
Cronos Group$25.64 million135.45$1.17 billion$0.6714.39

Cronos Group has lower revenue, but higher earnings than Mannatech.

Risk & Volatility

Mannatech has a beta of 1.09, suggesting that its stock price is 9% more volatile than the S&P 500. Comparatively, Cronos Group has a beta of 2.07, suggesting that its stock price is 107% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and target prices for Mannatech and Cronos Group, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Mannatech0000N/A
Cronos Group25202.00

Cronos Group has a consensus target price of $8.8333, suggesting a potential downside of 8.37%. Given Cronos Group's higher probable upside, analysts plainly believe Cronos Group is more favorable than Mannatech.

Profitability

This table compares Mannatech and Cronos Group's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Mannatech5.04%28.69%11.99%
Cronos Group266.31%-1.61%-1.41%

Insider & Institutional Ownership

15.0% of Mannatech shares are owned by institutional investors. Comparatively, 11.8% of Cronos Group shares are owned by institutional investors. 45.8% of Mannatech shares are owned by insiders. Comparatively, 7.9% of Cronos Group shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Cronos Group beats Mannatech on 7 of the 12 factors compared between the two stocks.

Mannatech (NASDAQ:MTEX) and USANA Health Sciences (NYSE:USNA) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, risk, dividends, earnings and valuation.

Analyst Recommendations

This is a summary of recent ratings and target prices for Mannatech and USANA Health Sciences, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Mannatech0000N/A
USANA Health Sciences00203.00

USANA Health Sciences has a consensus target price of $126.00, suggesting a potential upside of 25.92%. Given USANA Health Sciences' higher probable upside, analysts plainly believe USANA Health Sciences is more favorable than Mannatech.

Risk & Volatility

Mannatech has a beta of 1.09, suggesting that its stock price is 9% more volatile than the S&P 500. Comparatively, USANA Health Sciences has a beta of 0.98, suggesting that its stock price is 2% less volatile than the S&P 500.

Valuation and Earnings

This table compares Mannatech and USANA Health Sciences' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Mannatech$157.73 million0.24$3.29 millionN/AN/A
USANA Health Sciences$1.06 billion1.99$100.53 million$4.4122.71

USANA Health Sciences has higher revenue and earnings than Mannatech.

Insider & Institutional Ownership

15.0% of Mannatech shares are owned by institutional investors. Comparatively, 54.1% of USANA Health Sciences shares are owned by institutional investors. 45.8% of Mannatech shares are owned by insiders. Comparatively, 45.4% of USANA Health Sciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Mannatech and USANA Health Sciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Mannatech5.04%28.69%11.99%
USANA Health Sciences10.57%32.91%22.26%

Summary

USANA Health Sciences beats Mannatech on 10 of the 12 factors compared between the two stocks.

Aurora Cannabis (NYSE:ACB) and Mannatech (NASDAQ:MTEX) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, analyst recommendations, dividends, valuation, risk, profitability and institutional ownership.

Risk and Volatility

Aurora Cannabis has a beta of 3.44, meaning that its stock price is 244% more volatile than the S&P 500. Comparatively, Mannatech has a beta of 1.09, meaning that its stock price is 9% more volatile than the S&P 500.

Insider & Institutional Ownership

11.9% of Aurora Cannabis shares are held by institutional investors. Comparatively, 15.0% of Mannatech shares are held by institutional investors. 45.8% of Mannatech shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares Aurora Cannabis and Mannatech's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Aurora Cannabis-1,238.94%-16.32%-13.12%
Mannatech5.04%28.69%11.99%

Earnings and Valuation

This table compares Aurora Cannabis and Mannatech's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aurora Cannabis$207.89 million9.32$-2,468,190,000.00($2.86)-3.43
Mannatech$157.73 million0.24$3.29 millionN/AN/A

Mannatech has lower revenue, but higher earnings than Aurora Cannabis.

Analyst Ratings

This is a breakdown of current ratings and price targets for Aurora Cannabis and Mannatech, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Aurora Cannabis69001.60
Mannatech0000N/A

Aurora Cannabis presently has a consensus price target of $11.2445, suggesting a potential upside of 14.62%. Given Aurora Cannabis' higher possible upside, equities research analysts plainly believe Aurora Cannabis is more favorable than Mannatech.

Summary

Mannatech beats Aurora Cannabis on 7 of the 11 factors compared between the two stocks.


Mannatech Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Canopy Growth logo
CGC
Canopy Growth
0.8$31.01-7.2%$11.65 billion$297.34 million-9.28Decrease in Short Interest
Aphria logo
APHA
Aphria
1.3$16.71-8.8%$5.76 billion$405.96 million-28.32Gap Up
Tilray logo
TLRY
Tilray
1.0$22.65-11.7%$4.34 billion$166.98 million-4.99Gap Up
Cronos Group logo
CRON
Cronos Group
0.7$9.64-7.0%$3.47 billion$25.64 million40.17Earnings Announcement
Analyst Report
Analyst Revision
USANA Health Sciences logo
USNA
USANA Health Sciences
2.0$100.14-0.3%$2.11 billion$1.06 billion18.54Insider Selling
Aurora Cannabis logo
ACB
Aurora Cannabis
1.3$9.82-6.5%$2.06 billion$207.89 million-0.40Decrease in Short Interest
Sundial Growers logo
SNDL
Sundial Growers
1.0$1.16-12.1%$2.03 billion$75.86 million-0.45Increase in Short Interest
Gap Up
HEXO logo
HEXO
HEXO
0.9$6.52-7.4%$855.14 million$60.46 million-1.34
ChromaDex logo
CDXC
ChromaDex
0.9$9.58-19.1%$705.00 million$46.29 million-25.21Upcoming Earnings
MediWound logo
MDWD
MediWound
1.4$5.19-6.6%$150.62 million$31.79 million-12.97Earnings Announcement
Analyst Report
Decrease in Short Interest
Analyst Revision
Natural Alternatives International logo
NAII
Natural Alternatives International
0.4$14.49-0.8%$92.89 million$118.88 million181.15Increase in Short Interest
Gap Up
HAPP
Happiness Biotech Group
0.6$1.85-5.4%$50.51 million$65.06 million0.00
HUGE
FSD Pharma
0.3$1.78-9.0%$37.17 million$190,000.00-0.40Increase in Short Interest
Gap Up
CYAN
Cyanotech
0.6$3.55-5.9%$22.93 million$31.90 million35.50Decrease in Short Interest
News Coverage
This page was last updated on 3/4/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.